| Literature DB >> 35763169 |
Haiyuan Li1,2, Yang Yu2, Lei Gao2, Peng Zheng2, Xiaolong Liu2, Hao Chen3,4.
Abstract
Tissue factor (TF), an initiator of extrinsic coagulation pathway, is positively correlated with venous thromboembolism (VTE) of tumor patients. Beyond thrombosis, TF plays a vital role in tumor progression. TF is highly expressed in cancer tissues and circulating tumor cell (CTC), and activates factor VIIa (FVIIa), which increases tumor cells proliferation, angiogenesis, epithelial-mesenchymal transition (EMT) and cancer stem cells(CSCs) activity. Furthermore, TF and TF-positive microvesicles (TF+MVs) activate the coagulation system to promote the clots formation with non-tumor cell components (e.g., platelets, leukocytes, fibrin), which makes tumor cells adhere to clots to form CTC clusters. Then, tumor cells utilize clots to cause its reducing fluid shear stress (FSS), anoikis resistance, immune escape, adhesion, extravasation and colonization. Herein, we review in detail that how TF signaling promotes tumor metastasis, and how TF-targeted therapeutic strategies are being in the preclinical and clinical trials.Entities:
Keywords: Cancer biology; Coagulation pathway; Immune escape; Tissue factor
Mesh:
Substances:
Year: 2022 PMID: 35763169 DOI: 10.1007/s11239-022-02662-0
Source DB: PubMed Journal: J Thromb Thrombolysis ISSN: 0929-5305 Impact factor: 2.300